Related Experiment Video
Updated: Jul 9, 2025
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
New Insights into Cardiovascular Diseases Treatment Based on Molecular Targets
Armanda Wojtasińska1, Joanna Kućmierz1, Julita Tokarek1
1Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland.
Insights
New cardiovascular disease (CVD) treatments target molecular pathways and utilize technologies like SGLT-2 inhibitors and GLP-1 receptor agonists. Exosomes also show promise in understanding myocardial injury for improved CVD strategies.
Area of Science:
- Cardiology
- Endocrinology
- Molecular Biology
Background:
- Cardiovascular diseases (CVDs) are a leading cause of death globally, frequently co-occurring with diabetes mellitus and lipid disorders.
- These comorbidities complicate prognosis and treatment, necessitating novel therapeutic strategies.
- Emerging research explores new molecular targets and technologies for managing CVDs and associated conditions.
Purpose of the Study:
- To review current and emerging therapeutic targets and technologies for cardiovascular diseases (CVDs).
- To highlight the role of novel treatments for diabetes mellitus and dyslipidemia in managing CVDs.
- To explore the potential of exosomes in understanding and treating myocardial ischemia.
Main Methods:
- Review of current literature on CVDs, diabetes mellitus, and lipid disorders.
- Analysis of novel molecular targets such as PCSK9, angiopoietin-like protein 3, and ATP-citrate lyase.
- Examination of therapeutic technologies including siRNA, SGLT-2 inhibitors, and GLP-1 receptor agonists.
- Investigation of the role of exosomes in myocardial ischemia and injury.
Main Results:
- New therapies targeting PCSK9, angiopoietin-like protein 3, and ATP-citrate lyase are advancing dyslipidemia treatment.
- SGLT-2 inhibitors and GLP-1 receptor agonists, used for diabetes, demonstrate significant cardiovascular benefits.
- Exosomes are implicated in myocardial ischemia, with their levels correlating to injury severity.
Conclusions:
- Understanding novel molecular mechanisms and therapeutic technologies is crucial for advancing CVD treatment.
- Integrated management of CVDs with diabetes and lipid disorders requires exploring new targets and drug classes.
- Exosomes represent a promising area for future research in myocardial injury and CVD therapeutics.
Abstract:
Cardiovascular diseases (CVDs) which consist of ischemic heart disease, stroke, heart failure, peripheral arterial disease, and several other cardiac and vascular conditions are one of the most common causes of death worldwide and often co-occur with diabetes mellitus and lipid disorders which worsens the prognosis and becomes a therapeutic challenge. Due to the increasing number of patients with CVDs, we need to search for new risk factors and pathophysiological changes to create new strategies for preventing, diagnosing, and treating not only CVDs but also comorbidities like diabetes mellitus and lipid disorders. As increasing amount of patients suffering from CVDs, there are many therapies which focus on new molecular targets like proprotein convertase subtilisin/kexin type 9 (PCSK9), angiopoietin-like protein 3, ATP-citrate lyase, or new technologies such as siRNA in treatment of dyslipidemia or sodium-glucose co-transporter-2 and glucagon-like peptide-1 in treatment of diabetes mellitus. Both SGLT-2 inhibitors and GLP-1 receptor agonists are used in the treatment of diabetes, however, they proved to have a beneficial effect in CVDs as well. Moreover, a significant amount of evidence has shown that exosomes seem to be associated with myocardial ischaemia and that exosome levels correlate with the severity of myocardial injury. In our work, we would like to focus on the above mechanisms. The knowledge of them allows for the appearance of new strategies of treatment among patients with CVDs.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...